KOAN Quote, Financials, Valuation and Earnings

MultiCorp International, Inc. has a net margin of -107.63% compared to Resonate Blends, Inc.'s net margin of --. Resonate Blends, Inc.'s return on equity of -- beat MultiCorp International, Inc.'s return on equity of --.

Resonate Blends, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand MultiCorp International, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Resonate Blends, Inc. has higher upside potential than MultiCorp International, Inc., analysts believe Resonate Blends, Inc. is more attractive than MultiCorp International, Inc..

Resonate Blends, Inc. has a beta of 3.813, which suggesting that the stock is 281.291% more volatile than S&P 500. In comparison MultiCorp International, Inc. has a beta of 5.069, suggesting its more volatile than the S&P 500 by 406.92%.

Resonate Blends, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MultiCorp International, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Resonate Blends, Inc. pays -- of its earnings as a dividend. MultiCorp International, Inc. pays out -- of its earnings as a dividend.

Resonate Blends, Inc. quarterly revenues are $452.3K, which are larger than MultiCorp International, Inc. quarterly revenues of --. Resonate Blends, Inc.'s net income of -$486.8K is higher than MultiCorp International, Inc.'s net income of --. Notably, Resonate Blends, Inc.'s price-to-earnings ratio is -- while MultiCorp International, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Resonate Blends, Inc. is 0.30x versus -- for MultiCorp International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Mind Medicine (MindMed), Inc. has a net margin of -107.63% compared to Resonate Blends, Inc.'s net margin of --. Resonate Blends, Inc.'s return on equity of -- beat Mind Medicine (MindMed), Inc.'s return on equity of -80.63%.

Resonate Blends, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Mind Medicine (MindMed), Inc. has an analysts' consensus of $25.73 which suggests that it could grow by 112.1%. Given that Mind Medicine (MindMed), Inc. has higher upside potential than Resonate Blends, Inc., analysts believe Mind Medicine (MindMed), Inc. is more attractive than Resonate Blends, Inc..

Resonate Blends, Inc. has a beta of 3.813, which suggesting that the stock is 281.291% more volatile than S&P 500. In comparison Mind Medicine (MindMed), Inc. has a beta of 2.792, suggesting its more volatile than the S&P 500 by 179.161%.

Resonate Blends, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mind Medicine (MindMed), Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Resonate Blends, Inc. pays -- of its earnings as a dividend. Mind Medicine (MindMed), Inc. pays out -- of its earnings as a dividend.

Resonate Blends, Inc. quarterly revenues are $452.3K, which are larger than Mind Medicine (MindMed), Inc. quarterly revenues of --. Resonate Blends, Inc.'s net income of -$486.8K is higher than Mind Medicine (MindMed), Inc.'s net income of -$67.3M. Notably, Resonate Blends, Inc.'s price-to-earnings ratio is -- while Mind Medicine (MindMed), Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Resonate Blends, Inc. is 0.30x versus -- for Mind Medicine (MindMed), Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Phibro Animal Health Corp. has a net margin of -107.63% compared to Resonate Blends, Inc.'s net margin of 7.29%. Resonate Blends, Inc.'s return on equity of -- beat Phibro Animal Health Corp.'s return on equity of 24.77%.

Resonate Blends, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Phibro Animal Health Corp. has an analysts' consensus of $43.00 which suggests that it could grow by 5.91%. Given that Phibro Animal Health Corp. has higher upside potential than Resonate Blends, Inc., analysts believe Phibro Animal Health Corp. is more attractive than Resonate Blends, Inc..

Resonate Blends, Inc. has a beta of 3.813, which suggesting that the stock is 281.291% more volatile than S&P 500. In comparison Phibro Animal Health Corp. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.868%.

Resonate Blends, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phibro Animal Health Corp. offers a yield of 1.18% to investors and pays a quarterly dividend of $0.12 per share. Resonate Blends, Inc. pays -- of its earnings as a dividend. Phibro Animal Health Corp. pays out 40.46% of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Resonate Blends, Inc. quarterly revenues are $452.3K, which are smaller than Phibro Animal Health Corp. quarterly revenues of $363.9M. Resonate Blends, Inc.'s net income of -$486.8K is lower than Phibro Animal Health Corp.'s net income of $26.5M. Notably, Resonate Blends, Inc.'s price-to-earnings ratio is -- while Phibro Animal Health Corp.'s PE ratio is 24.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Resonate Blends, Inc. is 0.30x versus 1.18x for Phibro Animal Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Viridian Therapeutics, Inc. has a net margin of -107.63% compared to Resonate Blends, Inc.'s net margin of -49.03%. Resonate Blends, Inc.'s return on equity of -- beat Viridian Therapeutics, Inc.'s return on equity of -47.79%.

Resonate Blends, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Viridian Therapeutics, Inc. has an analysts' consensus of $40.19 which suggests that it could grow by 25.08%. Given that Viridian Therapeutics, Inc. has higher upside potential than Resonate Blends, Inc., analysts believe Viridian Therapeutics, Inc. is more attractive than Resonate Blends, Inc..

Resonate Blends, Inc. has a beta of 3.813, which suggesting that the stock is 281.291% more volatile than S&P 500. In comparison Viridian Therapeutics, Inc. has a beta of 0.914, suggesting its less volatile than the S&P 500 by 8.612%.

Resonate Blends, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viridian Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Resonate Blends, Inc. pays -- of its earnings as a dividend. Viridian Therapeutics, Inc. pays out -- of its earnings as a dividend.

Resonate Blends, Inc. quarterly revenues are $452.3K, which are smaller than Viridian Therapeutics, Inc. quarterly revenues of $70.6M. Resonate Blends, Inc.'s net income of -$486.8K is higher than Viridian Therapeutics, Inc.'s net income of -$34.6M. Notably, Resonate Blends, Inc.'s price-to-earnings ratio is -- while Viridian Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Resonate Blends, Inc. is 0.30x versus 36.85x for Viridian Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.